- Home
- Publications
- Publication Search
- Publication Details
Title
T-cell-independent Antitumor Effects of CD40 Ligation
Authors
Keywords
-
Journal
INTERNATIONAL REVIEWS OF IMMUNOLOGY
Volume 31, Issue 4, Pages 267-278
Publisher
Informa UK Limited
Online
2012-07-18
DOI
10.3109/08830185.2012.698337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.
- (2017) P. W. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors
- (2011) F. Aranda et al. CANCER RESEARCH
- Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
- (2011) T. S. Lewis et al. CLINICAL CANCER RESEARCH
- Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression
- (2011) Q. Li et al. CLINICAL CANCER RESEARCH
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- CD40-mediated cell death requires TRAF6 recruitment
- (2011) Malek Jundi et al. IMMUNOBIOLOGY
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma
- (2011) B. Burington et al. Science Translational Medicine
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial
- (2010) P.-U. Malmstrom et al. CLINICAL CANCER RESEARCH
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
- (2010) Ilia N. Buhtoiarov et al. IMMUNOLOGY
- CD40-activated B cells contribute to mesothelioma tumor regression
- (2010) Connie Jackaman et al. IMMUNOLOGY AND CELL BIOLOGY
- CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
- (2010) Anusha Kalbasi et al. JOURNAL OF IMMUNOTHERAPY
- Enhanced T-cell-independent Antitumor Effect of Cyclophosphamide Combined With Anti-CD40 mAb and CpG in Mice
- (2010) Erik E. Johnson et al. JOURNAL OF IMMUNOTHERAPY
- Regression of Established AB1 Murine Mesothelioma Induced by Peritumoral Injections of CpG Oligodeoxynucleotide Either Alone or in Combination with Poly(I:C) and CD40 Ligand Plasmid DNA
- (2010) Geoffrey W. Stone et al. Journal of Thoracic Oncology
- Biology and Clinical Applications of CD40 in Cancer Treatment
- (2010) Ester Fonsatti et al. SEMINARS IN ONCOLOGY
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in Cancer
- (2009) P.-Y. Pan et al. CANCER RESEARCH
- In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells
- (2009) U. K. Scarlett et al. CANCER RESEARCH
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy
- (2009) S. A. Broomfield et al. JOURNAL OF IMMUNOLOGY
- Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
- (2009) Erica L Carpenter et al. Journal of Translational Medicine
- Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma
- (2009) Geoffrey W. Stone et al. PLoS One
- The role of CD40 and CD154/CD40L in dendritic cells
- (2009) Daphne Y. Ma et al. SEMINARS IN IMMUNOLOGY
- Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
- (2008) E Oflazoglu et al. BRITISH JOURNAL OF CANCER
- CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors
- (2008) Alexander L. Rakhmilevich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
- (2008) Connie Jackaman et al. INTERNATIONAL IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started